Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28696036 | 0.82 | MAPK13 (0.46) | AHRENPP2EPAS1MAPK13CDK1 | |
| SCHEMBL3307757 | 0.73 | AHR (0.41) | AHRCSNK2A1MAPK13CDK1PIM1 | |
| SCHEMBL16029817 | 0.71 | ENPP2 (0.37) | ENPP2EPAS1 | |
| SCHEMBL3850787 | 0.69 | AHR (0.58) | AHRCSNK2A1 | |
| SCHEMBL15571232 | 0.67 | MAPT (0.37) | EPAS1 | |
| SCHEMBL11282194 | 0.67 | AHR (0.55) | AHRCSNK2A1 | |
| SCHEMBL2588191 | 0.66 | GRIA2 (0.46) | AHR | |
| SCHEMBL22065263 | 0.66 | AHR (0.35) | AHRCSNK2A1 | |
| SCHEMBL1701091 | 0.66 | AHR (0.39) | AHRCSNK2A1DYRK1A | |
| SCHEMBL29924706 | 0.66 | AHR (0.39) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-2970186-B1 | 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-2970186-B1 | 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-9090612-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090612-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2563759-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011139765-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139765-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | AHR 3487/4885ENPP2 418/4885CSNK2A1 1647/4885 |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | AHR 3487/4885ENPP2 418/4885CSNK2A1 1647/4885 |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | AHR 3487/4885ENPP2 418/4885CSNK2A1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.